首页> 外文期刊>Cancer Cell International >MiR-26a/miR-26b represses tongue squamous cell carcinoma progression by targeting PAK1
【24h】

MiR-26a/miR-26b represses tongue squamous cell carcinoma progression by targeting PAK1

机译:miR-26a / miR-26b通过靶向pak1来压制舌鳞状细胞癌进展

获取原文
           

摘要

Tongue squamous cell carcinoma (TSCC) is the most common oral malignancy. Previous studies found that microRNA (miR)-26a and miR-26b were downregulated in TSCC tissues. The current study was designed to explore the effects of miR-26a/miR-26b on TSCC progression and the potential mechanism. Expression of miR-26a, miR-26b and p21 Activated Kinase 1 (PAK1) in TSCC tissues and cell lines was detected by reverse transcription- quantitative polymerase chain reaction (RT-qPCR). Flow cytometry analysis was performed to examine cell cycle and apoptosis. Transwell assay was conducted to evaluate the migrated and invasive abilities of SCC4 and Cal27 cells. In addition, western blot assay was employed to analyze the protein level. Glucose assay kit and lactate assay kit were utilized to analyze glycolysis. Dual-luciferase reporter and RNA immunoprecipitation (RIP) assays were applied to explore the relationship between miR-26a/miR-26b and PAK1. Xenograft tumor model was constructed to explore the role of miR-26a/miR-26b in vivo. Both miR-26a and miR-26b were underexpressed, while PAK1 was highly enriched in TSCC. Overexpression of miR-26a and miR-26b inhibited TSCC cell cycle, migration invasion and glycolysis, while promoted cell apoptosis. Both miR-26a and miR-26b directly targeted and negatively regulated PAK1 expression. Introduction of PAK1 partially reversed miR-26a/miR-26b upregulation-mediated cellular behaviors in TSCC cells. Gain of miR-26a/miR-26b blocked TSCC tumor growth in vivo. MiR-26a/miR-26b repressed TSCC progression via targeting PAK1 in vitro and in vivo, which enriched our understanding about TSCC development and provided new insights into the its treatment.
机译:舌鳞状细胞癌(TSCC)是最常见的口腔恶性肿瘤。以前的研究发现,MicroRNA(miR)-26a和miR-26b在TSCC组织中下调。目前的研究旨在探讨miR-26a / miR-26b对TSCC进展和潜在机制的影响。通过逆转录定量聚合酶链反应(RT-QPCR)检测TSCC组织和细胞系中MiR-26a,miR-26b和p21活化激酶1(pak1)的表达。进行流式细胞术分析以检查细胞周期和细胞凋亡。进行Transwell测定以评估SCC4和CAL27细胞的迁移和侵袭能力。此外,使用Western印迹测定分析蛋白质水平。利用葡萄糖测定试剂盒和乳酸分析试剂盒来分析糖酵解。应用双荧光素酶报告和RNA免疫沉淀(RIP)测定以探讨miR-26a / miR-26b和pak1之间的关系。构建异种移植肿瘤模型以探讨miR-26a / miR-26b在体内的作用。 miR-26a和miR-26b都是缺陷的,而PAK1在TSCC中高度富集。 miR-26a和miR-26b的过表达抑制了TSCC细胞周期,迁移侵袭和糖酵解,同时促进细胞凋亡。 miR-26a和miR-26b都直接靶向和负调节的pak1表达。 PAK1的引入部分反转的MIR-26A / miR-26B上调介导的TSCC细胞中的细胞行为。 miR-26a / miR-26b的增益阻断了体内的TSCC肿瘤生长。 MiR-26A / MIR-26B通过靶向PAK1在体外和体内抑制TSCC进展,这丰富了我们对TSCC开发的理解,并为其治疗提供了新的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号